FDA approves argenx’s VYVGART Hytrulo for CIDP treatment
24 Jun 2024
Drug ApprovalClinical ResultPriority Review
Preview
Source: Pharmaceutical Technology
The asset is the first FcRn blocker approved for adults with chronic inflammatory demyelinating polyneuropathy. Credit: David Gyung / Shutterstock.
The US Food and Drug Administration (FDA) has approved Argenx‘s VYVGART Hytrulo to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Intended for use as a once-a-week 30-to-90-second subcutaneous injection, VYVGART Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker approved for this indication.
In February 2024, the US regulator accepted Argenx’s sBLA for VYVGART Hytrulo to treat CIDP, for priority review.
The FDA’s decision is grounded on results from the ADHERE study.
The study demonstrated that 69% of subjects treated with VYVGART Hytrulo, irrespective of prior treatment, showed clinical improvement including enhanced mobility, function and strength.
See Also:Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease
Preview
Source: Pharmaceutical Technology
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
Preview
Source: Pharmaceutical Technology
The trial also met its primary endpoint with a statistically significant 61% reduction in the risk of relapse compared to placebo.
99% of trial participants chose to continue in the ADHERE open-label extension.
The safety profile of VYVGART Hytrulo was in line with prior clinical studies and its real-world use, without any new safety concerns reported.
VYVGART Hytrulo is also approved in the US for generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
argenx chief medical officer Luc Truyen stated: “argenx continues to pursue our ambition to turn science into solutions for patients with severe autoimmunity.
“Patients have been waiting, and today argenx is delivering the first innovative treatment for CIDP in more than 30 years. VYVGART Hytrulo is a precision tool that has been shown to drive meaningful benefits for patients. The FDA approval means that CIDP patients have a transformational new treatment option and further affirms the therapeutic profile of VYVGART Hytrulo and the potential of FcRn blockade in IgG-mediated autoimmune diseases.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.